相关临床试验
0
0 进行中
药物批准
45
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
<p><strong>INDICATIONS</strong></p> <p>Desroxia is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.</p> <p>Desroxia is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:</p> <ul class="dash"> <li>in patients with other anaemias,</li> <li>in patients aged 2 to 5 years,</li> <li>in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells).</li> </ul> <p>Desroxia is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.</p>
<p><strong>INDICATIONS</strong></p> <p>Desroxia is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.</p> <p>Desroxia is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:</p> <ul class="dash"> <li>in patients with other anaemias,</li> <li>in patients aged 2 to 5 years,</li> <li>in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells).</li> </ul> <p>Desroxia is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.</p>
**4.1 Therapeutic indications** Fulvestrant is indicated: - As monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: - Not previously treated with endocrine therapy, or - With disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. - In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women with disease progression following endocrine therapy (see section 5.1). In pre- or perimenopausal women, the combination treatment with palbociclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
暂无资讯文章
